All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Do we need new endpoints to assess spleen response in MPN?

During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked: Do we need new endpoints to assess spleen response in MPN?

John Mascarenhas thinks yes, spleen-related endpoints used in clinical trials evaluating MPN-directed therapies should be reassessed. This interview highlights alternative MPN-related symptoms for consideration.

Do we need new endpoints to assess spleen response in MPN?

Share:
More about...